首页> 外文OA文献 >Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

【2h】

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

机译：含有HIV-1和透射的壬核苷逆转录酶抑制剂抗性突变治疗 - 幼稚嘧啶/胞藤/替诺夫韦富马酸薄荷（DOR / 3TC / TDF）的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Alexander Wong; Deborah Goldstein; Josep Mallolas; Edwin DeJesus; Margaret Johnson; Jean-Michel Molina; Anton Pozniak; Anthony Rodgers; Valerie Teal; Deborah Hepler; Sushma Kumar; Peter Sklar; George J. Hanna; Carey Hwang; Cyrus Badshah; Hedy Teppler;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations [J] . Wong Alexander, Goldstein Deborah, Mallolas Josep, JAIDS: Journal of acquired immune deficiency syndromes . 2019,第4期

机译：用HIV-1和透射的壬核苷逆转录酶抑制剂抗损伤治疗野生成年人的多亚氟/拉米夫鲁维尔/替诺夫罗疹富马酸薄荷酸的疗效和安全性（DOR / 3TC / TDF）
2. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial [J] . Johnson Margaret, Kumar Princy, Molina Jean-Michel, JAIDS: Journal of acquired immune deficiency syndromes . 2019,第4期

机译：切换到Doravirine / Lamivudine / Tenofovir Disoproxil富马酸盐（DOR / 3TC / TDF）通过48周维持HIV-1病毒学抑制：驱动转移试验的结果
3. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide [J] . Margot Nicolas A., Wong Pamela, Kulkarni Rima, The Journal of Infectious Diseases . 2017,第6期

机译：抗逆转录酶及抗逆转录病毒治疗 - 幼稚患者的常态HIV-1耐药性突变和蛋白酶的蛋白酶，并对含有替替替洛韦富马酸的方案或替诺福韦醛酰胺的反应
4. The effects of nonnucleoside reverse transcriptase inhibitor resistance mutations on human immunodeficiency virus type 1 replication and reverse transcriptase function. [D] . Gerondelis, Peter. 2001

机译：非核苷类逆转录酶抑制剂耐药性突变对人免疫缺陷病毒1型复制和逆转录酶功能的影响。
5. LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial [O] . Princy Kumar, Margaret Johnson, Jean-Michel Molina, -1

机译：LB2。切换至Doravirine /拉米夫定/替诺福韦富马酸二甲酚（DOR / 3TC / TDF）可以在48周内保持病毒学抑制：DRIVE-SHIFT试验的结果
6. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial [O] . Chloe Orkin, Kathleen E Squires, Jean-Michel Molina, 2020

机译：Doravirine / Lamivudine / Tenofovir Disoproxil umarate（tdf）与efavirenz / Emtricicabine / tdf在治疗 - 天真的成人与人类免疫缺陷病毒1型感染：周96个随机，双盲，第3阶段推进的不合理试验

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

著录项

引文网络

相似文献

相关主题

期刊订阅